Immunotherapy combo trial aims to outsmart aggressive breast cancer
NCT ID NCT03414684
Summary
This study is testing if adding an immunotherapy drug called nivolumab to standard chemotherapy (carboplatin) works better for controlling advanced triple-negative breast cancer that has spread. It involved 78 patients whose cancer had not been treated for its spread. The main goal was to see if the combination helps keep the cancer from growing for a longer period compared to chemotherapy alone.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02115, United States
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02115, United States
-
Dana-Farber/Brigham and Women's Cancer Center at Milford Regional Medical Center
Milford, Massachusetts, 01757, United States
-
Dana-Farber/Brigham and Women's Cancer Center in clinical affiliation with South Shore Hospital
South Weymouth, Massachusetts, 02190, United States
-
Dana-Farber/New Hampshire Oncology-Hematology
Londonderry, New Hampshire, 03053, United States
-
Eastern Maine Medical Center
Bangor, Maine, 04401, United States
-
Ohio State University
Columbus, Ohio, 43210, United States
-
St. Elizabeth's Medical Center
Boston, Massachusetts, 02135, United States
-
The Stamford Hospital
Stamford, Connecticut, 06904, United States
-
University of Vermont Medical Center
Burlington, Vermont, 05401, United States
Conditions
Explore the condition pages connected to this study.